The COVID-19 outbreak caused by SARS-CoV-2 in late 2019 has spread rapidly across the world to form a global epidemic of respiratory infectious diseases. Increased investigations on diagnostic tools are currently implemented to assist rapid identification of the virus because mass and rapid diagnosis might be the best way to prevent the outbreak of the virus. This critical review discusses the detection principles, fabrication techniques, and applications on the rapid detection of SARS-CoV-2 with three categories: rapid nuclear acid augmentation test, rapid immunoassay test and biosensors. Special efforts were put on enhancement of nanomaterials on biosensors for rapid, sensitive, and low-cost diagnostics of SARS-CoV-2 virus. Future developments are suggested regarding potential candidates in hospitals, clinics and laboratories for control and prevention of large-scale epidemic. Graphical Abstract
Stent implantation is widely used to treat coronary artery disease, yet in-stent restenosis (ISR) remains a major clinical challenge. Fractional flow reserve (FFR) is the gold-standard index for evaluating restenosis severity, but current techniques are invasive and unsuitable for continuous monitoring. Here, we present a bioresorbable smart stent platform that enables real-time intravascular pressure sensing and continuous FFR monitoring. The system integrates a MEMS-based LC pressure sensor, fabricated from SU-8 and gold, onto a hybrid 3D-printed vascular stent composed of polycaprolactone (PCL) and polylactic acid (PLA). Structural refinements and an optimized fabrication process enable long-term sensor reliability, minimize signal drift, and maintain stable resonance frequency. Across 100 fabricated devices, the pressure sensors show a resonance frequency of 82.2 ± 1.7 MHz and a sensitivity of 37.48 ± 2.13 kHz/mmHg. In vitro closed-loop fluidic tests using a vascular phantom confirmed the stable, wireless operation of the device and its ability to accurately assess hemodynamic parameters. The dual-sensor configuration enables simultaneous upstream and downstream pressure measurements, yielding FFR values that closely match those from a commercial system (R² = 0.97) under varying stenosis severities. The proposed smart stent offers a promising pathway toward long-term, non-invasive vascular monitoring and early detection of ISR.